Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 21, 2022; 28(23): 2561-2568
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2561
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2561
Table 2 Combination therapy trials
Trial therapies | Study name | Phase | Patient number or estimation | ORR | Median PFS | Median OS |
Lenvatinib + TACE vs Lenvatinib[47] | LAUNCH | Phase 3 | 338 | 54.1% vs 25% | 10.6 mo vs 6.4 mo | 17.8 mo vs 11.5 mo |
(cTACE or DEB-TACE) + durvalumab followed by durvalumab + placebo vs (DEB-TACE or cTACE) + durvalumab followed by durvalumab + bevacizumab vs (DEB-TACE or cTACE)[48] | EMERLD | Phase 3 | 600 | In progress | In progress | In progress |
Lenvatinib + Pembrolizumab + TACE vs Placebo + TACE[49] | LEAP-012 | Phase 3 | 950 | In progress | In progress | In progress |
Nivolumab + Ipilimumab + TACE vs Nivolumab + Placebo + TACE vs Placebo + Placebo + TACE[50] | Checkmate-74W | Phase 3 | 765 | In progress | In progress | In progress |
Brivanib + TACE vs Placebo + TACE[51] | BRISK-TA | Phase 3 | 502 | 48% vs 42% | 8.4 mo vs 4.9 mo1 | 26.4 mo vs 26.1 mo |
Oranitib + TACE vs Placebo + TACE[52] | ORIENTAL | Phase 3 | 889 | Not reported | 2.9 mo vs 2.5 mo1 | 31.1 mo vs 32.3 mo |
Tremelimumab + TACE[53] | Phase 2 | 11 | 18% | 7.4 mo1 | 13.6 mo |
- Citation: Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol 2022; 28(23): 2561-2568
- URL: https://www.wjgnet.com/1007-9327/full/v28/i23/2561.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i23.2561